Cencora Inc (N:COR)

Business Focus: Medical Equipment, Supplies & Distribution

Feb 06, 2025 08:37 pm ET
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Feb 05, 2025 06:30 am ET
Cencora Reports Fiscal 2025 First Quarter Results
Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 13.7 percent to $3.73 in the fiscal first quarter from $3.28 in the prior year first quarter.
Jan 08, 2025 07:30 am ET
Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025.
Jan 02, 2025 04:15 pm ET
Cencora Completes Acquisition of Retina Consultants of America
Cencora, Inc. (NYSE: COR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists.
Dec 09, 2024 04:15 pm ET
Cencora Closes $1.8 Billion Senior Notes Offering
Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement C
Dec 02, 2024 10:49 pm ET
Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with
Nov 06, 2024 06:35 am ET
Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.02 for the September quarter of fiscal 2024, compared to $1.72 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 16.8 percent to $3.34 in the fiscal fourth quarter. For fiscal year 2024,
Nov 06, 2024 06:30 am ET
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners.
Nov 04, 2024 08:30 am ET
Cencora Expands Enterprise Leadership Team with Two Senior Appointments
Cencora, Inc. (NYSE: COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora’s enterprise leadership team, bringing their extensive experience and expertise to help advance the company’s pharmaceutical-centric strategy and drive growth for Cencora and its customers.
Oct 01, 2024 07:30 am ET
Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024.
Aug 15, 2024 07:30 am ET
Cencora Elects Frank Clyburn to Its Board of Directors
Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Frank Clyburn as a new independent director, effective October 1, 2024. With the election of Mr. Clyburn, the Board of Directors will increase to thirteen members.
Jul 31, 2024 06:30 am ET
Cencora Reports Fiscal 2024 Third Quarter Results
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 14.4 percent to $3.34 in the fiscal third quarter from $2.92 in the prior year third quarter.
Jul 08, 2024 08:35 am ET
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that the United...
Jul 05, 2024 04:15 pm ET
Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024.
Apr 05, 2024 08:30 am ET
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024.
Mar 12, 2024 08:30 am ET
Cencora Announces Leadership Succession Plan
Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024. Robert P. Mauch, PharmD, PhD, current Chief Operating Officer of Cencora, will succeed Collis as President and CEO, and will also be appointed as a member of the Company's Board, effective the same date.
Feb 07, 2024 06:26 pm ET
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Feb 07, 2024 06:16 pm ET
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million.
Feb 07, 2024 01:11 pm ET
Cencora Closes $500 Million Senior Notes Offering
Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021.
Feb 05, 2024 06:18 pm ET
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. The offering is expected to close on February 7, 2024, subject to the satisfaction of customary closing conditions. Cencora intends to use the net proceeds from the offering to redeem all of its 3.400% Senior Notes due May 15, 2024
Jan 31, 2024 06:30 am ET
Cencora Reports Fiscal 2024 First Quarter Results
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.
Jan 04, 2024 04:30 pm ET
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024.
Nov 22, 2023 08:00 am ET
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
BOSTON, Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.
Nov 09, 2023 06:58 pm ET
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.
Nov 02, 2023 06:30 am ET
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. Revenue increased 9.9 percent to $262.2 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0 percent to $2.86 in the fisc
Oct 02, 2023 04:30 pm ET
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023.
Aug 30, 2023 07:30 am ET
AmerisourceBergen becomes Cencora, in alignment with the company’s growing global footprint and central role in pharmaceutical access and care
Cencora, Inc. (NYSE: COR) today announced the completion of its name and stock ticker change from AmerisourceBergen Corporation (NYSE: ABC), marking the latest stage of the company’s evolution as a leader in global pharmaceutical services. Cencora will begin trading under the new ticker symbol “COR” on the New York Stock Exchange at the open of the market trading today, August 30, 2023.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.